Patents by Inventor Jo SOURBRON

Jo SOURBRON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
    Publication number: 20220193082
    Abstract: Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.
    Type: Application
    Filed: January 19, 2022
    Publication date: June 23, 2022
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Peter De Witte, Lieven Lagae, Jo Sourbron, Bradley S. Galer
  • COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
    Publication number: 20180325909
    Abstract: Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.
    Type: Application
    Filed: May 25, 2018
    Publication date: November 15, 2018
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Peter De Witte, Lieven Lagae, Jo Sourbron, Bradley S. Galer
  • COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
    Publication number: 20170071949
    Abstract: Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.
    Type: Application
    Filed: September 14, 2016
    Publication date: March 16, 2017
    Applicant: ZOGENIX INTERNATIONAL LIMITED
    Inventors: Peter DE WITTE, Lieven LAGAE, Jo SOURBRON, Bradley S. GALER